1

                                                                    EXHIBIT 99.1

ViroLogic, Inc. (ticker: VLGC, exchange: NASDAQ) News Release - 2-Jul-2001

VIROLOGIC ANNOUNCES $16.25 MILLION PRIVATE PLACEMENT

SOUTH SAN FRANCISCO, Calif., Jul 2, 2001 /PRNewswire/ -- ViroLogic, Inc.
(Nasdaq: VLGC) today announced it has entered into an agreement to sell newly
issued shares of 6% convertible preferred stock to several large investors in
two separate placements, with expected gross proceeds to the company totaling
$16.25 million. The sale of a portion of the shares closed today, with the
Company receiving $6.65 million in proceeds. UBS Warburg and CIBC World Markets
are serving as advisors for this transaction.

ViroLogic expects to use the net proceeds from this financing to support and
enhance ongoing commercial activities, accelerate research and development of
new products, and for general administrative expenses, capital expenditures and
working capital.

"This financing significantly strengthens our balance sheet," said Bill Young,
ViroLogic's Chairman and CEO. "It comes at a great time as we step up our
efforts in the field to continue to increase sales as we have over the last two
quarters and prepare new products for commercialization later this year. In
addition, we expect the proceeds will fund development of our pipeline focused
on patient management and drug development assays for hepatitis B and C."

ViroLogic's flagship product, PhenoSense(TM) HIV, is a rapid, highly sensitive
drug resistance assay that allows physicians to directly and reliably measure
the level of clinically significant HIV drug resistance. With this information,
physicians can individualize treatment regimens for their patients to maintain
effective therapy and avoid unnecessary side effects, resulting in improved
outcomes and reduced treatment costs. Pharmaceutical companies are also using it
to develop new drugs to which HIV might be less resistant.

The preferred stock will be convertible into common stock at a premium to the
current market price. The purchasers will also receive warrants to purchase a
total of 3.2 million shares of common stock, at an exercise price that is also
at a premium to the current market price. The second closing of the private
placement is subject to certain conditions, including approval of the Company's
shareholders. The offer and sale of the securities being sold by ViroLogic in
the private placements will not be and has not been registered under the
Securities Act of 1933, as amended, and may not be sold by ViroLogic absent
registration or an applicable exemption from registration requirements. However,
the Company has agreed to file a registration statement for the resale of the
shares underlying the preferred stock and the warrants, as well as shares
issuable as dividends on the preferred stock. This news release is not an offer
to sell, or a solicitation of an offer to buy, the securities discussed herein.

About ViroLogic

ViroLogic is a biotechnology company advancing the fields of individualized
medicine and pharmacogenomics, helping to make them realities in healthcare
around the world today. The Company discovers, develops and markets innovative
products to guide and improve treatment of serious viral diseases such as AIDS
and hepatitis. Its leading expertise in virology, molecular biology, clinical
research, engineering, information systems, and quality assurance has resulted
in technology to assess drug resistance and susceptibility in viruses that cause
these diseases, which affect millions of people worldwide.

The Company's current products are designed to optimize HIV/AIDS treatment
regimens, providing physicians with important information to help select
appropriate drugs for their patients and leading to better outcomes and reduced
costs. These products are also being used by major pharmaceutical companies to
develop new and improved antiviral therapeutics targeted at emerging
drug-resistant viruses.


   2

Certain statements in this press release are forward-looking, including
statements relating to the offer and sale of shares of preferred stock and the
issuance of warrants and shareholder approval thereof, as well as anticipated
uses of proceeds and potential pipeline and product development efforts. These
forward-looking statements are subject to risks and uncertainties and other
factors, which may cause actual results to differ materially from the
anticipated results or other expectations expressed in such forward-looking
statements. These risks and uncertainties include, but are not limited to, an
inability to consummate the private placement, an inability to obtain
shareholder approval for the second closing, an inability to effectively use
anticipated proceeds as contemplated, whether planned pipeline and product
development efforts will be successful, whether PhenoSense(TM) testing will
achieve market acceptance, whether payers will authorize reimbursement for our
products, whether we will be able to expand our sales and marketing
capabilities, whether we encounter problems or delays in automating our process,
whether we successfully introduce new products using our PhenoSense technology,
including entry and fitness assays, whether intellectual property underlying our
PhenoSense technology is adequate, whether we are able to build brand loyalty,
the ability to raise additional capital, and other risks and uncertainties
detailed from time to time in our reports to the Securities and Exchange
Commission, including our Annual Report on Form 10-K for the year ended December
31, 2000 and the Company's most recent Report on Form 10-Q.